Showing all 2 results
Alpelisib Tablets
FreeProduct Composition & Strength
We supply this product in standardized daily dose packs, designed to achieve the 300 mg daily therapeutic target.
Active Ingredient Strength Primary Clinical Function Alpelisib USP/Ph.Eur. 50 mg / 150 mg The Combination Unit: Used together (150mg x 2) to reach the standard 300mg daily dose. Alpelisib USP/Ph.Eur. 200 mg The Dose-Reduction Unit: Used for patients requiring a lower dose due to side effects (Hyperglycemia/Rash). Excipients Proprietary Matrix Bio-Stable Coating: Engineered to protect the sensitive API and ensure consistent systemic absorption. Capecitabine Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Cytotoxic Tablet, packed in high-barrier Alu-Alu blister strips to ensure the stability of the active API.
Active Ingredient Strength Primary Clinical Function Capecitabine USP/Ph.Eur. 150 mg The Precision Titration Anchor: Utilized for accurate dose adjustments based on Body Surface Area (BSA). Capecitabine USP/Ph.Eur. 500 mg The Oncology Macrodose: The primary therapeutic unit for standard cycles in Colorectal and Breast cancer. Excipients Proprietary Matrix High-Containment Coating: Engineered with an impenetrable film-coat to prevent the release of cytotoxic dust during handling by healthcare professionals.
